Expertise in
28
conditions

Dr. Luke P. Dreisbach

Internal Medicine
Office
34490 Bob Hope Dr, 
Rancho Mirage, CA 
Offers Telehealth
Expertise in
28
conditions
Office
34490 Bob Hope Dr, 
Rancho Mirage, CA 

Overview

Luke Dreisbach is a primary care provider, practicing in Internal Medicine in Rancho Mirage, California.

Dr. Dreisbach is highly rated in 28 conditions, according to our data. His clinical expertise encompasses Colorectal Cancer, Lung Cancer, Familial Colorectal Cancer, and Postmenopausal Osteoporosis.

He is actively involved in clinical research, co-authoring 2 peer reviewed articles and participating in 10 clinical trials.

Specialties

Internal Medicine

Licenses

Internal Medicine in CA

Hospital Affiliations

Desert Regional Medical Center
Palo Verde Hospital
Eisenhower Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Inland Empire Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 17 Less Insurance Carriers -

Locations

Office
34490 Bob Hope Dr, Rancho Mirage, CA 92270

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAF V600E/K Mutant Melanoma
A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAF V600E/K Mutant Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Drug
Study Drugs: Dabrafenib Mesylate, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 2
Phase 3, Open-Label, 4-Cohort Study of Nogapendekin Alfa Inbakicept in Combination With Current Standard of Care as First-Line Treatment for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
Phase 3, Open-Label, 4-Cohort Study of Nogapendekin Alfa Inbakicept in Combination With Current Standard of Care as First-Line Treatment for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
Enrollment Status: Terminated
Publish Date: May 26, 2026
Intervention Type: Drug
Study Drugs: N-803+Pembrolizumab, N-803+Carboplatin+Nab-paclitaxel+Pembrolizumab, N-803+Cisplatin or Carboplatin+Pembrolizumab+Pemetrexed, Pembrolizumab, Carboplatin+Nab-paclitaxel or Paclitaxel+Pembrolizumab, Cisplatin or Carboplatin+Pembrolizumab+Pemetrexed
Study Phase: Phase 3
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)
Enrollment Status: Active_not_recruiting
Publish Date: April 02, 2026
Intervention Type: Drug
Study Phase: Phase 3
The National Myelodysplastic Syndromes Natural History Study
The National Myelodysplastic Syndromes Natural History Study
Enrollment Status: Completed
Publish Date: February 03, 2026
Intervention Type: Other
QUILT-3.055: A Phase IIb, Multicohort, Open-Label Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With PD-1/PD-L1 Immune Checkpoint Inhibitors
QUILT-3.055: A Phase IIb, Multicohort, Open-Label Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With PD-1/PD-L1 Immune Checkpoint Inhibitors
Enrollment Status: Active_not_recruiting
Publish Date: January 14, 2026
Intervention Type: Drug
Study Drugs: N-803, Pembrolizumab, Nivolumab, Atezolizumab, Avelumab, Durvalumab, PD-L1 t-haNK
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 31, 2024
Intervention Type: Drug
Study Drug: Fuzuloparib+Abiraterone Acetate+Prednisone
Study Phase: Phase 3
A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects With Waldenström's Macroglobulinemia (WM)
A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects With Waldenström's Macroglobulinemia (WM)
Enrollment Status: Completed
Publish Date: October 26, 2024
Intervention Type: Drug
Study Drugs: BGB-3111 (Zanubrutinib), Ibrutinib
Study Phase: Phase 3
A Phase III Open-label, Multicenter Trial of Maintenance Therapy With Avelumab (MSB0010718C) Versus Continuation of First-line Chemotherapy in Subjects With Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro-esophageal Junction
A Phase III Open-label, Multicenter Trial of Maintenance Therapy With Avelumab (MSB0010718C) Versus Continuation of First-line Chemotherapy in Subjects With Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro-esophageal Junction
Enrollment Status: Completed
Publish Date: June 09, 2022
Intervention Type: Drug, Other
Study Phase: Phase 3
A Multicenter, Open-Label, Randomized-Controlled Study of Abemaciclib, a CDK4 and 6 Inhibitor, in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer With Visceral Metastases
A Multicenter, Open-Label, Randomized-Controlled Study of Abemaciclib, a CDK4 and 6 Inhibitor, in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer With Visceral Metastases
Enrollment Status: Terminated
Publish Date: August 24, 2021
Intervention Type: Drug
Study Phase: Phase 4
A 2-Arm Phase 2 Double-Blind Randomized Study of Carboplatin, Pemetrexed Plus Placebo Versus Carboplatin, Pemetrexed Plus Truncated Demcizumab as First-Line Treatment in Subjects With Stage IV Non-Squamous Non-Small Cell Lung Cancer
A 2-Arm Phase 2 Double-Blind Randomized Study of Carboplatin, Pemetrexed Plus Placebo Versus Carboplatin, Pemetrexed Plus Truncated Demcizumab as First-Line Treatment in Subjects With Stage IV Non-Squamous Non-Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: September 09, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

2 Total Publications

Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial.
Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial.
Journal: Nature medicine
Published: May 07, 2020
Similar Doctors
Expertise in
10
conditions
Dr. Ann E. Stapleton
Internal Medicine
Expertise in
10
conditions
Dr. Ann E. Stapleton
Internal Medicine

Eisenhower Health

39000 Bob Hope Dr, 
Rancho Mirage, CA 
 (1.5 miles away)
760-340-3911
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ann Stapleton is a primary care provider, practicing in Internal Medicine in Rancho Mirage, California. Dr. Stapleton is highly rated in 10 conditions, according to our data. Her clinical expertise encompasses Urinary Tract Infection (UTI), Asymptomatic Bacteriuria, HIV/AIDS, and Myelitis.

Expertise in
36
conditions
Expertise in
36
conditions
Before you request

Eisenhower Health

39000 Bob Hope Dr, 
Rancho Mirage,, CA 
 (1.5 miles away)
760-346-0642
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Chanaka Wickramasinghe is a primary care provider, practicing in Internal Medicine in Rancho Mirage,, California. Dr. Wickramasinghe is highly rated in 36 conditions, according to our data. His clinical expertise encompasses Nasal Flaring, Familial Hypertension, Glucocorticoid-Remediable Aldosteronism, and Hypertension. Dr. Wickramasinghe is currently accepting new patients.

Expertise in
23
conditions
Dr. James C. Moon
Internal Medicine
Expertise in
23
conditions
Dr. James C. Moon
Internal Medicine

Jerry L. Pettis Memorial Veterans' Hospital

11201 Benton St, 
Loma Linda, CA 
 (50.9 miles away)
909-825-7084
Languages Spoken:
English
See accepted insurances

James Moon is a primary care provider, practicing in Internal Medicine in Loma Linda, California. Dr. Moon is highly rated in 23 conditions, according to our data. His clinical expertise encompasses Cardiomyopathy, Hypertrophic Cardiomyopathy (HCM), Fabry Disease, Aortic Valve Replacement, and Tissue Biopsy.

Frequently Asked Questions about Dr. Luke P. Dreisbach

How do I make an appointment with Dr. Luke P. Dreisbach?

You can book an appointment with Dr. Luke P. Dreisbach by calling their office at 760-568-3613. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Luke P. Dreisbach a top-rated expert for Colorectal Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Luke P. Dreisbach is classified as an Distinguished expert for Colorectal Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Luke P. Dreisbach specialize in?

While Dr. Luke P. Dreisbach is a Internal Medicine, they have specific expertise in Colorectal Cancer, Lung Cancer, and Familial Colorectal Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Internal Medicine.

Does Dr. Luke P. Dreisbach participate in research or clinical trials?

Yes. Dr. Luke P. Dreisbach has published 2 articles and abstracts on conditions like Colorectal Cancer. You can view a list of Dr. Luke P. Dreisbach's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Luke P. Dreisbach accept my insurance?

Dr. Luke P. Dreisbach accepts most major insurance plans, including Aetna and Alignment Health Plan. We recommend calling the office directly at 760-568-3613 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Dreisbach's expertise for a condition
ConditionClose
    View All 23 Advanced Conditions
    View All 93 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile